Read more about the requirements for taking part in joint testing on the Kanta Services website:
Situation of the Prescription service
Abilita Hälsovård / Abilita Oy Ab
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20102016 / 30.12.2016 |
| Functionality for action on behalf of a minor |
20072020 / 14.9.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20122022 / 8.2.2022 |
| The 2022 changes of the Pharmaceutical Database | 20022023 / 1.2.2023 |
Acute / Vitec Acute Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Structured dosage | 25.3.2025 | Ongoing, 29.4.2025 | Not tested | Not tested |
| FHIR interface to search for identifiers | 25.3.2025 | Ongoing, 13.5.2025 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20012016 / 30.11.2016 |
| Functionality for action on behalf of a minor | 20072021 / 14.9.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20032022 / 3.2.2022 |
| The 2022 changes of the Pharmaceutical Database | 20272022 / 5.10.2022 |
Altti2 / Fujitsu Finland Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Joint testing of the Prescription service |
20142023 / 29.5.2023 |
Apotti / Apotti Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Structured dosage | 19.3.2025 | Ongoing, 28.4.2025 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information |
20022018 / 5.10.2018 |
| Functionality for action on behalf of a minor | 20192022 / 2.5.2022 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (Prescription's HL7 specifications 3.42) | 20182022 / 29.4.2022 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (Prescription's HL7 specifications 3.63) | 20212022 / 5.5.2022 |
| The 2022 changes of the Pharmaceutical Database | 20032023 / 25.1.2023 |
AssisDent / Entteri Professional Software Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Structured dosage | 28.3.2025 | Ongoing, 12.5.2025 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20062016 / 27.12.2016 |
| Functionality for action on behalf of a minor | 20062021 / 30.6.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 27.4.2022 / 20162022 |
| The 2022 changes of the Pharmaceutical Database | 20052023 / 8.3.2023 |
| Testing of interoperability (Testing of system changes) | 20182023 / 25.8.2023 |
DomaCare / Invian Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20142017 / 7.3.2017 |
| Functionality for action on behalf of a minor | 20032021 / 4.5.2021 |
| Refusal to share prescription information | 20052021 / 29.6.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 29.4.2022 / 20172022 |
| The 2022 changes of the Pharmaceutical Database | 20022025 / 30.4.2025 |
DynamicHealth / Tietoevry Oyj
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Structured dosage | 14.1.2025 | Completed, 16.6.2025 | Not tested | Not tested |
| Structured dosage (DynamicHealth eResepti Interface) | 26.3.2025 | Ongoing, 4.4.2025 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20032016 / 30.12.2016 |
| Functionality for action on behalf of a minor |
20122020 / 20.11.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20022022 / 2.2.2022 |
| The 2022 changes of the Pharmaceutical Database | 20042023 / 2.2.2023 |
| Prescription's MR and CDA R2 specifications 4.00 and requirement specifications 3.00 (DynamicHealth eResepti Interface) | 20112023 / 26.4.2023 |
ERA / Atostek Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20092016 / 29.12.2016 |
| Functionality for action on behalf of a minor |
20032020 / 16.3.2020 |
| Functionality for action on behalf of a minor (testing of system changes) |
20052020 / 10.8.2020 |
| The 2022 version of the Pharmaceutical Database | 20102022 / 11.4.2022 |
| Structured dosage | 20112022 / 12.4.2022 |
| FHIR interface to search for identifiers | 20082022 / 22.3.2022 |
ESKO / Esko Systems Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Structured dosage | 27.5.2025 | Not started | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20022016 / 9.12.2016 |
| Functionality for action on behalf of a minor | 20012022 / 31.1.2022 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20132022 / 11.4.2022 |
| The 2022 changes of the Pharmaceutical Database | 20302022 / 27.10.2022 |
Hilkka / FastROI Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20082016 / 30.12.2016 |
| Refusal to share prescription information |
20012018 / 11.1.2018 |
| Functionality for action on behalf of a minor | 20022021 / 12.4.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20152022 / 26.4.2022 |
| The 2022 version of the Pharmaceutical Database | 20072023 / 4.4.2023 |
| Structured dosage | 20132023 / 11.5.2023 |
KEJO/ Patria Aviation Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Search and viewing of data concerning prescriptions and dispensations |
20142020 / 23.11.2022 |
| Functionality for action on behalf of a minor | 20012025 / 3.1.2025 |
Kelain / Kela
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20042016 / 13.12.2016 |
| Refusal to share prescription information |
20202017 / 1.6.2017 |
| Functionality for action on behalf of a minor |
20012020 / 14.1.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20042022 / 3.2.2022 |
| The 2022 changes of the Pharmaceutical Database | 20282022 / 13.10.2022 |
| Structured dosage | 20292022 / 13.10.2022 |
Lifecare / Tietoevry Oyj
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Kanta medication list, phase 2 system forward compatibility | 31.3.2025 | Not started | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20192017 / 11.5.2017 |
| Functionality for action on behalf of a minor | 20102021 / 18.11.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20062022 / 23.2.2022 |
| The 2022 version of the Pharmaceutical Database | 20062023 / 24.3.2023 |
| Structured dosage | 20152023 / 2.6.2023 |
| FHIR interface to search for identifiers | 20162023 / 13.6.2023 |
MAXX FI/ Receptum Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20122017 / 11.1.2017 |
| Cross-border prescription |
20012019 / 30.9.2019 |
| Functionality for action on behalf of a minor |
20062020 / 8.9.2020 |
| The 2022 changes of the Pharmaceutical Database | 20252022 / 29.4.2022 |
| Structured dosage | 20262022 / 29.4.2022 |
| Code identifying a prescribed medicine at the pharmacy | 20082023 / 13.4.2023 |
Mediatri / Mediconsult Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
|
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20072016 / 30.12.2016 |
| Refusal to share prescription information |
20212017 / 6.6.2017 |
| Functionality for action on behalf of a minor |
20042020 / 8.10.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20072022 / 17.2.2022 |
| The 2022 changes of the Pharmaceutical Database | 20322022 / 28.11.2022 |
Mediatri Saga / Mediconsult Oyj
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's HL7 specifications 3.63 and functional specification 2.94 |
20312022 / 4.11.2022 |
| The 2022 version of the Pharmaceutical Database | 20172023 / 16.8.2023 |
Mediresepti / Mediconsult Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20132016 / 30.12.2016 |
| Refusal to share prescription information |
20222017 / 4.12.2017 |
| Functionality for action on behalf of a minor |
20132020 / 26.11.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20092022 / 22.3.2022 |
| The 2022 version of the Pharmaceutical Database | 20192023 / 13.10.2023 |
Norre / Norre Työterveys Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0 |
25.8.2022 | Discontinued | Not started | Not started |
Omapd / Pharmadata Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0 | 20012023 / 1.2.2023 |
| Code identifying a prescribed medicine at the pharmacy | 20102023 / 26.4.2023 |
OMNI360 Terveydenhuolto / CGI Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Forward compatibility of the Kanta medication list, phase | 8.5.2025 | Ongoing, 8.5.2025 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20052016 / 20.12.2016 |
| Functionality for action on behalf of a minor (OMNI360 Kertomus) |
20012021 / 21.1.2021 |
| Functionality for action on behalf of a minor | 20082021 / 14.9.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (OMNI360 Kertomus) | 20122021 / 18.11.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20052022 / 24.2.2022 |
| The 2022 changes of the Pharmaceutical Database (OMNI360 Kertomus) | 20342022 / 20.12.2022 |
| Structured dosage | 20032025 / 6.5.2025 |
| FHIR interface to search for identifiers | 20062025/ 26.5.2025 |
pd3 / Pharmadata Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20172017 / 27.1.2017 |
|
Cross-border prescription |
20022020 / 20.2.2020 |
| Functionality for action on behalf of a minor |
20102020 / 24.9.2020 |
| Structured dosage | 3.5.2022 / 20242022 |
| The 2022 changes of the Pharmaceutical Database | 3.5.2022 / 20232022 |
| Code identifying a prescribed medicine at the pharmacy | 20092023 / 26.4.2023 |
Sairec / CGI Oy
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 4.1.1 and requirement specifications 3.1.1 |
20202023 / 20.10.2023 |
Uranus-potilastietojärjestelmä / CGI Oy
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
| Forward compatibility of the Kanta medication list, phase | 12.5.2025 | 12.5.2025 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20152017 / 11.1.2017
|
| Functionality for action on behalf of a minor | 20042021 / 16.6.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database |
20112021 / 18.11.2021 |
| The 2022 changes of the Pharmaceutical Database | 20332022 / 20.12.2022 |
| Structured dosage | 20042025 / 12.5.2025 |
| FHIR interface to search for identifiers | 20052025 / 12.5.2025 |